Edwards Lifesciences (NYSE: EW) stock price increased 10% in the after-market trading as the second-quarter results surpassed estimates. In addition, the company has raised its full-year outlook. However, the Q3 adjusted earnings guidance range fell short of consensus by 2 cents.
Post the positive PARTNER 3 Trial results, the stock touched a new 52-week high eclipsing $197 mark in March. The stock momentum continued due to the solid Q1 results with the share price up about 28% in 2019.
Thanks to solid product sales across the board, sales increased 15% to $1.1 billion while adjusted EPS grew 11% to $1.38. Last quarter, Edwards projected Q2 sales of $1.02-1.08 billion and adjusted EPS of $1.27-1.37.
On the flip side, analysts were expecting sales to grow about 8% to $1.04 billion and adjusted EPS of $1.33 compared to $1.24 reported last year. Edwards reported better-than-expected results on both the top and bottom-line numbers.
CEO Michael A. Mussallem when commenting on the firm’s potential stated: “As patients and clinicians increasingly understand the significant benefits of transcatheter-based technologies, supported by the substantial body of compelling evidence, we remain as optimistic as ever about the long-term growth opportunity.”
On the products’ front, Edwards expects the Food and Drug Administration (FDA) to give the nod for SAPIEN 3 valve and SAPIEN 3 Ultra devices in the third quarter for treating patients with low surgical risk.
Edwards has revised upwards its 2019 guidance. It expects sales in the range of $4-4.3 billion and adjusted EPS of $5.20-5.40. The street is anticipating revenues of $4.16 billion and adjusted earnings of $5.29 per share.
For the Q3 period, the company is expecting the top line to be between $1.02-1.06 billion and adjusted EPS of $1.13-1.23. However, analysts are expecting sales to improve 10.6% to $1.02 billion and adjusted earnings of $1.25 per share, which is 2 cents more than the high-end EPS forecast provided by the firm.
Micron Technology Inc. (NASDAQ: MU) Thursday said its fourth-quarter profit declined from last year, hurt by a sharp fall in revenues. Earnings, however, beat the market’s projection. On an adjusted
Shares of Philip Morris International Inc. (NYSE: PM) were down 1% on Thursday. The stock has dropped over 9% year-to-date. Although the tobacco industry has felt the pinch of inflation,
CarMax, Inc. (NYSE:KMX) reported second quarter 2023 earnings results today. Net revenues rose 2% year-over-year to $8.1 billion. Net earnings were $125.9 million, or $0.79 per share, compared to $285.2 million,